Can Fite Biopharma (CANF.TA) Stock Price
Can Fite Biopharma Price
Revenue at Can Fite Biopharma has contracted by 11.2% per year over the past 19 years to 438,400.00 USD. Can Fite Biopharma's net margin stands at -2,426.7%, down from -1,476.6% several years earlier. Analysts set a median price target of 3.27 USD, implying 265.2% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Can Fite Biopharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Can Fite Biopharma business model & stock analysis
Frequently asked questions about Can Fite Biopharma
The business model of Can Fite Biopharma Ltd focuses on developing and commercializing novel drugs to address unmet medical needs. As a biopharmaceutical company, Can Fite specializes in the discovery, research, and development of innovative therapies. Through its research and development efforts, Can Fite aims to create effective and safe treatments for various medical conditions, including autoimmune diseases and cancer. By leveraging its expertise in drug development, Can Fite Biopharma Ltd strives to bring breakthrough therapies to market, improving patients' quality of life and providing value to shareholders.
Can Fite Biopharma Ltd is primarily active in the pharmaceutical industry.
The main competitors of Can Fite Biopharma Ltd in the market include notable pharmaceutical companies such as Pfizer Inc., Novartis AG, and Johnson & Johnson. These companies also operate in the biopharmaceutical industry, offering a diverse range of products and solutions for various medical conditions. Can Fite Biopharma Ltd competes with these industry giants by utilizing its proprietary technologies and innovative approaches to developing novel therapies. By constantly innovating and focusing on its research and development efforts, Can Fite Biopharma Ltd strives to differentiate itself in the market and provide unique therapeutic solutions to patients in need.
Can Fite Biopharma Ltd is a leading biopharmaceutical company specializing in the development of innovative therapeutics for the treatment of inflammatory and liver diseases. Established in 2000, Can Fite has since made significant advancements in the field of medicine. With a strong focus on utilizing small molecules to target disease pathways, Can Fite has garnered immense recognition for its groundbreaking research and development initiatives. The company has successfully developed multiple drug candidates, such as Namodenoson, which is currently in various stages of clinical trials. Can Fite Biopharma Ltd's commitment to advancing medical treatments and improving patients' lives remains at the forefront of their operations.
Can Fite Biopharma Ltd has achieved several significant milestones. The company successfully completed Phase II clinical trials for its drug candidate, Namodenoson, which demonstrated positive results in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, Can Fite Biopharma Ltd received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for Namodenoson in the treatment of HCC. The company also initiated Phase III clinical trials for Namodenoson in the treatment of liver cancer, showcasing their commitment to advancing this potential breakthrough therapy. Can Fite Biopharma Ltd's milestones illustrate its dedication to developing innovative treatments for HCC patients.
Can Fite Biopharma Ltd is primarily present in Israel.
Can Fite Biopharma Ltd represents values of innovation, scientific excellence, and commitment to patients' well-being. With a corporate philosophy rooted in advancing medical treatments, Can Fite Biopharma strives to develop and commercialize innovative therapies for challenging diseases. The company's efforts are centered around discovering and optimizing small molecule drugs, harnessing their potential to target and modulate disease-related pathways effectively. Can Fite Biopharma emphasizes collaboration, ensuring the best minds in the scientific community contribute to the development and progression of groundbreaking therapies. By staying at the forefront of research, Can Fite Biopharma Ltd aims to provide hope and improved outcomes for patients worldwide.
Analysts currently set an average price target of 3.27 USD for the Can Fite Biopharma stock (median: 3.27 USD), implying +265.2 % versus the latest price. The consensus is based on 7 analyst ratings.
8 analysts currently rate the Can Fite Biopharma stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Can Fite Biopharma to generate revenue of 404,000.00 USD and earnings per share of -0.00 USD.
Converted at the current exchange rate, the Can Fite Biopharma share trades at 0.80 EUR (0.90 USD).
Can Fite Biopharma Ltd is a leading biopharmaceutical company specializing in the development of innovative therapeutics for the treatment of inflammatory diseases and cancer. The company's business model is based on creating a wide portfolio of drugs that primarily target cellular signaling mechanisms. One of Can Fite Biopharma's main product lines is Small Molecule Therapeutic Candidates. These molecules are used in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. They have been designed to modulate the activity of specific enzymes and signaling pathways involved in the development and progression of these conditions. Another important product division of Can Fite Biopharma is the Patented Platform Technology. This technology is based on the development of peptides that specifically bind to proteins and thereby influence their activation or inhibition. It enables the development of drugs against target molecules that are otherwise difficult to reach. One example is the peptide drug Namodenoson, which specifically binds to the entry channels of liver cells and therefore represents a potential therapy for liver cancer. Additionally, Can Fite Biopharma is also involved in research and development in the field of RNA interference (RNAi). This technology allows for the targeted silencing of genes that play a role in the development of cancer or inflammatory diseases. Can Fite Biopharma has already begun identifying specific genes and developing RNAi therapeutics. The company distributes its products through licensing agreements with other pharmaceutical companies and medical research organizations in various parts of the world. Research and development are conducted in close collaboration with academic and clinical institutions. Can Fite Biopharma pursues an intensive patent strategy to protect its technologies and products. The company has already applied for and received a large number of patents in various countries. This secures Can Fite Biopharma a competitive advantage in the market for biopharmaceutical therapeutics. Overall, Can Fite Biopharma's business model is focused on expanding and diversifying its broad portfolio of therapeutics and technologies for the treatment of cancer and inflammatory diseases. Strategic partnerships with other companies and institutions, as well as an intensive patent strategy, are intended to ensure the long-term success of Can Fite Biopharma.
The expected revenue of Can Fite Biopharma is 404,000.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Can Fite Biopharma is -7,099.15 USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Can Fite Biopharma is currently -272.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Can Fite Biopharma stock.
The price-to-sales ratio (P/S) of Can Fite Biopharma is currently 4.78. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Can Fite Biopharma stock.
The Eulerpool Quality Score for Can Fite Biopharma is 3/10.
The ISIN of Can Fite Biopharma is IL0010944739. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Can Fite Biopharma is CANF.TA. The ticker symbol is used to trade Can Fite Biopharma shares on the stock exchange.
Can Fite Biopharma stock
Can Fite Biopharma Peer Group
Can Fite Biopharma FIGI
All fundamentals and in-depth analysis of Can Fite Biopharma
Our stock analysis for Can Fite Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Can Fite Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.